Molly Oosthuysen
Family · Knoxville, TNNPI 1154786937
Payments from drug & device makers
Across 112 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$360
- CSL Behring$268
- AstraZeneca$250
- Hospira, Inc.$227
- Takeda Pharmaceuticals U.S.A., Inc.$212
- Sanofi$192
- plus $698 from 10 others
What the payments were for
- Food & beverage$2,206100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 15 | $360 |
| CSL Behring | 13 | $268 |
| AstraZeneca | 15 | $250 |
| Hospira, Inc. | 9 | $227 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $212 |
| Sanofi | 11 | $192 |
| GSK | 9 | $167 |
| Genentech USA, Inc. | 9 | $158 |
| Grifols USA, LLC | 5 | $100 |
| Biocryst US Sales Co., LLC | 4 | $87 |
| Amgen | 4 | $68 |
| Pfizer | 2 | $35 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| Novartis | 1 | $21 |
| Octapharma USA, Inc. | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $15 |
How this compares
$2,206 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,168 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,620 |
| Epinephrine | 12 | $2,363 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $1,159 |
| Ipratropium Bromide | 15 | $546 |
| Levocetirizine Dihydrochloride | 15 | $54 |
| Montelukast Sodium | 13 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $167 | $17,78833 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $2,36312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.
Other family in Knoxville
- Dana WebberKnoxville$499K
- Tiffany SipeKnoxville$87K
- Ashley BonnellKnoxville$49K
- Stacey MaltmanKnoxville$34K
- Katherine JohnsonKnoxville$32K
- Ashley BellKnoxville$22K
- Carol HawkinsKnoxville$22K
- Mina FarrarKnoxville$21K
- Amy AllenKnoxville$21K
- Sarah HarderKnoxville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.